ArticleVirus research2026
Prognostic prediction in COVID-19 patients: a comprehensive analysis of gut microbiota and hematological biomarkers.
Article in Virus research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study investigates gut microbiota dynamics in COVID-19 patients and evaluates the prognostic potential of clinical hematological indicators. We collected 293 fecal samples from 225 confirmed COVID-19 cases (January-March 2023). After excluding samples with missing information, those from patients receiving Traditional Chinese Medicine, and those failing quality control, 169 samples from 169 unique patients were retained for 16S rRNA sequencing to assess gut microbiota composition and function in relation to disease severity, clinical scores (CURB65, qSOFA, PSI), and patient demographics. Results revealed significant changes in the microbiota, with critical cases showing reduced alpha diversity (Chao1, P < 0.01) and distinct beta diversity patterns compared to moderate/severe groups. Taxonomic profiling revealed significant microbiota changes associated with COVID-19 severity. Specifically, moderate cases exhibited an enriched abundance of Lachnospiraceae, whereas critical patients showed increased Streptococcaceae levels. Notably, Bacteroides abundance was significantly reduced in high-risk patients. Functional annotation further revealed that these taxonomic shifts were accompanied by distinct metabolic pathway disruptions, which correlated with disease severity progression. Concurrently, hematological markers (hematocrit, total bilirubin, albumin, sodium, hemoglobin) strongly correlated with disease progression. Our findings demonstrate that severe COVID-19 is associated with gut dysbiosis, which may exacerbate disease pathogenesis, and highlight the utility of blood biomarkers in predicting clinical outcomes, providing new insights for risk stratification and therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.